DK1326961T3 - Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner - Google Patents

Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner

Info

Publication number
DK1326961T3
DK1326961T3 DK01968626T DK01968626T DK1326961T3 DK 1326961 T3 DK1326961 T3 DK 1326961T3 DK 01968626 T DK01968626 T DK 01968626T DK 01968626 T DK01968626 T DK 01968626T DK 1326961 T3 DK1326961 T3 DK 1326961T3
Authority
DK
Denmark
Prior art keywords
aberrant cell
selective
pathologically aberrant
mixture
target antigens
Prior art date
Application number
DK01968626T
Other languages
Danish (da)
English (en)
Inventor
Antonella Vitiello
Rita Maccario
Daniela Montagna
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1326961T3 publication Critical patent/DK1326961T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
DK01968626T 2000-09-15 2001-09-06 Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner DK1326961T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23300900P 2000-09-15 2000-09-15
PCT/US2001/028016 WO2002022648A2 (fr) 2000-09-15 2001-09-06 Compositions et methodes destinees a induire des reponses cytolytiques specifiques chez des lymphocytes t

Publications (1)

Publication Number Publication Date
DK1326961T3 true DK1326961T3 (da) 2008-01-07

Family

ID=22875500

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01968626T DK1326961T3 (da) 2000-09-15 2001-09-06 Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner

Country Status (12)

Country Link
US (1) US20020119121A1 (fr)
EP (1) EP1326961B1 (fr)
JP (1) JP2004512030A (fr)
AT (1) ATE371017T1 (fr)
AU (1) AU2001288863A1 (fr)
CA (1) CA2422454A1 (fr)
CY (1) CY1107802T1 (fr)
DE (1) DE60130130T2 (fr)
DK (1) DK1326961T3 (fr)
ES (1) ES2292619T3 (fr)
PT (1) PT1326961E (fr)
WO (1) WO2002022648A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
US7651686B2 (en) * 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
ATE483469T1 (de) * 2002-07-12 2010-10-15 Univ Johns Hopkins Reagenzien und verfahren zum eingriff in einzigartige klonotype lymphozyten-rezeptoren
CA2536735C (fr) * 2003-09-05 2013-01-22 Genencor International, Inc. Methodes permettant d'identifier les epitopes des lymphocytes t cd8+
JP2007507543A (ja) * 2003-10-06 2007-03-29 セダーズ−シナイ メディカル センター 樹状細胞治療によって誘導されるｔ細胞アネルギーを予防するためのｃｏｘ−２インヒビターの使用
US7939090B2 (en) * 2003-10-21 2011-05-10 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
PT1814580T (pt) * 2004-11-24 2016-11-11 Hutchinson Fred Cancer Res Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais
US7745209B2 (en) 2005-07-26 2010-06-29 Corning Incorporated Multilayered cell culture apparatus
ITMI20052018A1 (it) * 2005-10-21 2007-04-22 Univ Bari Linea cellulare di carcinoma renale e suo uso
WO2007082154A2 (fr) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research Methode permettant de detecter un cancer a l'aide de b7-h1 et de b7-h4
EP2084267B1 (fr) 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Vaccins comprenant des antigenes de cellules souches cancereuses et procedes
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
AU2007307206B2 (en) 2006-10-04 2016-02-11 Janssen Pharmaceutica, N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
JP5366820B2 (ja) 2006-12-07 2013-12-11 ウィルソン ウォルフ マニュファクチャリング コーポレイション 細胞培養に効果的な装置および方法
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
DK2427485T3 (en) 2009-05-07 2017-03-13 Immunocellular Therapeutics Ltd CD133 epitopes
US9057054B2 (en) * 2009-06-25 2015-06-16 The Regents Of The University Of Michigan Antigen-specific long-term memory T-cells
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
WO2011060205A1 (fr) 2009-11-11 2011-05-19 The Trustees Of Columbia University In The City Of New York Procedes, compositions et dosages pour determiner l'effet d'une cellule immunitaire sur une cellule de maladie infectieuse ou neoplasique
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
KR101749195B1 (ko) 2011-12-12 2017-06-20 셀 메디카 리미티드 T 세포들을 증식시키는 방법
HRP20221303T1 (hr) 2012-02-09 2022-12-23 Baylor College Of Medicine SMJESE PEPTIDA ZA NASTAJANJE MULTIVIRUSNIH CITOTOKSIČNIH T-LIMFOCITA(CTLs) ŠIROKE SPECIFIČNOSTI
CA2898474A1 (fr) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Vaccins contre le cancer et methodes de vaccination
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2015050663A1 (fr) 2013-10-01 2015-04-09 Mayo Foundation For Medical Education And Research Procédés de traitement du cancer chez des patients présentant des taux élevés de bim
US10627411B2 (en) * 2014-03-27 2020-04-21 British Columbia Cancer Agency Branch T-cell epitope identification
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
WO2016014148A1 (fr) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Ciblage d'adn-pkcs et de b7-h1 pour traiter le cancer
WO2017075571A1 (fr) 2015-10-30 2017-05-04 Children's National Medical Center Génération de lymphocytes t spécifiques contre l'antigène du vph à partir d'une population de lymphocytes t naïfs
IL298359A (en) 2015-09-18 2023-01-01 Baylor College Medicine Immunogenic detection of antigen from a pathogen and adjustment of effective clinical treatment
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
US9642906B2 (en) 2016-09-16 2017-05-09 Baylor College Of Medicine Generation of HPV-specific T-cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002156A1 (fr) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Procedes d'utilisation de cellules dendritiques pour activer des lymphocytes t
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
CA2321093A1 (fr) * 1998-02-20 1999-08-26 The Rockefeller University Presentation des antigenes aux lymphocytes t au moyen de cellules d'apoptose
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes

Also Published As

Publication number Publication date
PT1326961E (pt) 2007-10-02
EP1326961B1 (fr) 2007-08-22
DE60130130T2 (de) 2008-05-15
US20020119121A1 (en) 2002-08-29
CA2422454A1 (fr) 2002-03-21
CY1107802T1 (el) 2013-06-19
WO2002022648A2 (fr) 2002-03-21
EP1326961A2 (fr) 2003-07-16
JP2004512030A (ja) 2004-04-22
ES2292619T3 (es) 2008-03-16
WO2002022648A3 (fr) 2002-05-30
AU2001288863A1 (en) 2002-03-26
EP1326961A4 (fr) 2005-11-09
DE60130130D1 (de) 2007-10-04
ATE371017T1 (de) 2007-09-15

Similar Documents

Publication Publication Date Title
DK1326961T3 (da) Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner
Maldini et al. CAR T cells for infection, autoimmunity and allotransplantation
Mason et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy
Ndure et al. Targeting regulatory T cells to improve vaccine immunogenicity in early life
Taniguchi et al. Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
Frimpong-Boateng et al. Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFβ
BRPI0414443A (pt) imunógenos consensuais/ancestrais
Zhang et al. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion
Thompson et al. Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants
van den Boorn et al. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG
Lynch et al. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
Rocco et al. Regulatory T cells: the ultimate HIV reservoir?
IL139950A0 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
MX2024002903A (es) Generacion alternativa de celulas t humanas alogeneicas.
Wen et al. Immunogenicity and cross‐reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma
Xiao-wen et al. Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting
Kurihara et al. Potential immunogenicity of adult T cell leukemia cells in vivo
Choi et al. The function of memory CD8+ T cells in immunotherapy for human diseases
Ishii et al. A combination of check-point blockade and α-galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo
Sfondrini et al. Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice
IL189615A0 (en) Melanoma vaccine and methods of making and using same
Li et al. Cooperation of invariant NKT cells and CD4+ CD25+ T regulatory cells in prevention of autoimmune diabetes in non‐obese diabetic mice treated with α‐galactosylceramide
Vevis et al. Characterization of antigen-binding and MHC class II-bearing T cells with suppressive activity in response to tolerogenic stimulus
Page et al. Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine
Montoya et al. Innate immune defenses in HIV-1 infection: prospects for a novel immune therapy